^
    5d
    DTP-HER2: A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric Cancer (clinicaltrials.gov)
    P2, N=76, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Tevimbra (tislelizumab-jsgr) • Aidixi (disitamab vedotin) • Kolupin (tunlametinib)
    27d
    Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=55, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Erbitux (cetuximab) • Kolupin (tunlametinib) • Dupert (fulzerasib)
    1m
    Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, Chinese PLA General Hospital
    New P2 trial
    |
    RAS mutation
    |
    Erbitux (cetuximab) • Kolupin (tunlametinib) • TheraCIM (nimotuzumab)
    1m
    RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma (clinicaltrials.gov)
    P4, N=110, Recruiting, Fudan University
    New P4 trial • Real-world evidence
    |
    NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    NRAS mutation
    |
    Kolupin (tunlametinib)
    3ms
    Melanoma: Pathogenesis and Targeted Therapy. (PubMed, MedComm (2020))
    In recent years, MEK inhibitors like binimetinib and tunlametinib have displayed the efficacy for NRASmut melanoma, with tunlametinib being the first and only approved MEK inhibitor for advanced NRASmut melanoma. Subsequently, we explored current and potential treatment approaches for melanoma, primarily encompassing BRAF inhibitors, MEK inhibitors, and immunotherapy, with a particular focus on their clinical relevance of development. Finally, the challenges in the treatment of melanoma, particularly in immunotherapy and targeted therapy, are summarized and discussed.
    Review • Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden) • NRAS (Neuroblastoma RAS viral oncogene homolog) • NF1 (Neurofibromin 1)
    |
    TMB-H • BRAF mutation • NRAS mutation
    |
    Mektovi (binimetinib) • Kolupin (tunlametinib)
    3ms
    Tunlametinib + AG + Cetuximab β as First-Line Therapy for Advanced Pancreatic Cancer (clinicaltrials.gov)
    P4, N=28, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P4 trial
    |
    Erbitux (cetuximab) • gemcitabine • albumin-bound paclitaxel • Kolupin (tunlametinib)
    5ms
    Multimodal treatment with thiotepa, bevacizumab, teniposide, and tunlametinib in a patient with neurofibromatosis type 1-associated oligodendroglioma: a rare case report. (PubMed, Anticancer Drugs)
    As of June 2025, the patient has achieved a CR with a progression-free survival of 9 months before experiencing disease recurrence. This rare case of NF1-associated oligodendroglioma was managed with thiotepa, bevacizumab, teniposide, and tunlametinib, highlighting the potential of MEK inhibition in NF1-related gliomas.
    Journal
    |
    NF1 (Neurofibromin 1)
    |
    Avastin (bevacizumab) • Kolupin (tunlametinib) • Vumon (teniposide) • thiotepa
    7ms
    Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors (clinicaltrials.gov)
    P2, N=15, Recruiting, Tianjin Medical University Second Hospital
    New P2 trial
    |
    MSK-IMPACT
    |
    Kolupin (tunlametinib)
    8ms
    IIT-085-TC-002: Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer (clinicaltrials.gov)
    P2, N=40, Recruiting, Fudan University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Kolupin (tunlametinib)
    8ms
    A prospective, single-arm, open-label exploratory clinical study evaluating the efficacy and safety of the combination therapy of toramatinib, vemurafenib and cetuximab in the first-line treatment of unresectable or advanced BRAF V600E mutant colorectal cancer (ChiCTR2500105081)
    P4, N=5, Not yet recruiting, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine; Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
    New P4 trial
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600 • BRAF positive
    |
    Erbitux (cetuximab) • Zelboraf (vemurafenib) • Kolupin (tunlametinib)
    8ms
    Characterization of 12 Unknown Photodegradation Impurities of Tunlametinib Capsules Using Liquid Chromatography Coupled With ion Trap/Time-Of-Flight Mass Spectrometry. (PubMed, Rapid Commun Mass Spectrom)
    Structural elucidation of 12 previously uncharacterized photodegradation impurities was achieved through HPLC/IT-TOF MS. These findings establish a scientific foundation for refining quality specifications of tunlametinib.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    Kolupin (tunlametinib)
    10ms
    A Study Evaluating the Efficacy and Safety of Torametinib (HL085) in Combination with Fruquintinib and Hydroxychloroquine (HCQ) in Patients with RAS/BRAFV600E Mutation-Positive Refractory Advanced Colorectal Cancer (ChiCTR2500102053)
    P2, N=38, Not yet recruiting, Peking Union Medical College Hospital; Peking Union Medical College Hospital
    New P2 trial
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    BRAF V600E • KRAS mutation • NRAS mutation • BRAF V600 • RAS mutation • NRAS Q61 • KRAS Q61
    |
    Fruzaqla (fruquintinib) • Kolupin (tunlametinib) • hydroxychloroquine